Clinical Trial Detail

NCT ID NCT02015728
Title Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
Recruitment Unknown status
Gender both
Phase Phase I
Variant Requirements no
Sponsors Seattle Children's Hospital
Indications

brain cancer

Therapies

Erlotinib

Everolimus

Dasatinib

Etoposide + Temozolomide

Sorafenib

Age Groups: adult child

No variant requirements are available.